Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryohei Katayama

Showing results (71-80 of 107) with videos related to

Pageof 11
Sort By:
Oncogene|December 11, 2024
Frequent copy number gain of MCL1 is a therapeutic target for osteosarcomaSatoshi Takagi, Mikako Nakajima, Sumie Koike, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2014
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinibRyohei Katayama, Luc Friboulet, Sumie Koike, et al.
Cancer Treatment and Research Communications|January 20, 2026
Phase 1/2 trial of brigatinib plus panitumumab in patients with osimertinib-resistant EGFR-mutated non-small cell lung cancer harboring EGFR C797S mutationHiroki Izumi, Tomohiro Sakamoto, Ken Uchibori, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancerRyo Ariyasu, Shingo Nishikawa, Ken Uchibori, et al.
NPJ Precision Oncology|May 13, 2026
The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinibMai Nagasaka, Francesco Facchinetti, Ludovic Bigot, et al.
Cell Reports|April 27, 2022
The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targetsKenji Ito, Kohei Nagata, Sho Ohta, et al.
NPJ Precision Oncology|February 24, 2024
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancerMai Suzuki, Ken Uchibori, Tomoko Oh-Hara, et al.
Ebiomedicine|January 22, 2019
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistanceKoutaroh Okada, Mitsugu Araki, Takuya Sakashita, et al.
JCI Insight|December 7, 2021
Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylationRay Sagawa, Seiji Sakata, Bo Gong, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 24, 2020
Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung CancerSachiko Arai, Shinji Takeuchi, Koji Fukuda, et al.
Pageof 11

Showing results (71-80 of 107) with videos related to

Sort By:
Pageof 11
Oncogene|December 11, 2024
Frequent copy number gain of MCL1 is a therapeutic target for osteosarcomaSatoshi Takagi, Mikako Nakajima, Sumie Koike, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2014
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinibRyohei Katayama, Luc Friboulet, Sumie Koike, et al.
Cancer Treatment and Research Communications|January 20, 2026
Phase 1/2 trial of brigatinib plus panitumumab in patients with osimertinib-resistant EGFR-mutated non-small cell lung cancer harboring EGFR C797S mutationHiroki Izumi, Tomohiro Sakamoto, Ken Uchibori, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancerRyo Ariyasu, Shingo Nishikawa, Ken Uchibori, et al.
NPJ Precision Oncology|May 13, 2026
The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinibMai Nagasaka, Francesco Facchinetti, Ludovic Bigot, et al.
Cell Reports|April 27, 2022
The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targetsKenji Ito, Kohei Nagata, Sho Ohta, et al.
NPJ Precision Oncology|February 24, 2024
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancerMai Suzuki, Ken Uchibori, Tomoko Oh-Hara, et al.
Ebiomedicine|January 22, 2019
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistanceKoutaroh Okada, Mitsugu Araki, Takuya Sakashita, et al.
JCI Insight|December 7, 2021
Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylationRay Sagawa, Seiji Sakata, Bo Gong, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 24, 2020
Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung CancerSachiko Arai, Shinji Takeuchi, Koji Fukuda, et al.
Pageof 11